[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Lichen Planus - Pipeline Insight, 2019

October 2019 | 60 pages | ID: L11566710177EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Lichen Planus - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lichen Planus pipeline landscape is provided which includes the disease overview and Lichen Planus treatment guidelines. The assessment part of the report embraces, in depth Lichen Planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen Planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Lichen Planus Understanding

Lichen Planus (LP) is a chronic, immunologically mediated mucocutaneous disease that can affect mucosal surfaces including those that line the oral cavity. It may affect the skin (cutaneous lichen planus), oral cavity (oral lichen planus), genitalia (penile or vulvar lichen planus), scalp (lichen planopilaris), nails, or esophagus. Oral lichen planus may be present in several forms, appearing alone or in combination, namely as Reticular, Atrophic/erosive and Plaque like oral lichen planus. According to the Canadian Dental Association, Reticular oral lichen planus form is the most common among all the other three forms. The majority of patients with oral lesions also have cutaneous lesions and the presence of these characteristics can aid in the diagnosis of OLP. The symptoms of Lichen Planus may begin abruptly or gradually, and the initial attack may persist for weeks or months. The primary spots are 2 to 4 mm in diameter with angular borders (a violet color and a distinct sheen in cross-lighting). According to the American Academy of Oral Medicine, females are predominantly more affected with Lichen Planus than males.

Lichen Planus Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lichen Planus targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lichen Planus pipeline report covers 8+ companies. Some of the key players include AFYX Therapeutics (Clobetasol Propionate), Celgene (Apremilast), Intas Pharmaceuticals (Nanosomal tacrolimus) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Lichen Planus Analytical Perspective by DelveInsight
  • In-depth Lichen Planus Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Lichen Planus Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Lichen Planus report provides an overview of therapeutic pipeline activity for Lichen Planus across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Lichen Planus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Lichen Planus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lichen Planus
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Lichen Planus to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Lichen Planus R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Lichen Planus in licensing and out licensing strategies by identifying prospective partners with progressing projects for Lichen Planus to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. LICHEN PLANUS

2.1. Lichen Planus Disease Overview
2.2. Lichen Planus History
2.3. Lichen Planus Symptoms
2.4. Lichen Planus Causes
2.5. Lichen Planus Pathophysiology
2.6. Lichen Planus Diagnosis
  2.6.1. Diagnostic Guidelines

3. LICHEN PLANUS CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. LICHEN PLANUS - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Lichen Planus companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Lichen Planus Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Lichen Planus Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. LICHEN PLANUS PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. LICHEN PLANUS -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Clobetasol Propionate- AFYX Therapeutics
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. Apremilast- Celgene
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table
  6.1.3. Nanosomal tacrolimus- Intas Pharmaceuticals
    6.1.3.1. Product Description
      6.1.3.1.1. Product Overview
      6.1.3.1.2. Mechanism of Action
    6.1.3.2. Research and Development
      6.1.3.2.1. Clinical Studies
        6.1.3.2.1.1. Detailed Study Description
        6.1.3.2.1.2. Study Results
        6.1.3.2.1.3. Clinical Trials: Tabular View
    6.1.3.3. Product Development Activities
      6.1.3.3.1. Tabulated Product Summary
        6.1.3.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. LICHEN PLANUS KEY COMPANIES

8.1. AFYX Therapeutics
8.2. Incyte Corporation
8.3. Takeda
8.4. Kiniksa Pharmaceuticals
8.5. Celgene
8.6. Intas Pharmaceuticals
8.7. Onxeo
8.8. Intas Pharmaceuticals

9. LICHEN PLANUS KEY PRODUCTS

9.1. Clobetasol propionate oral
9.2. Ruxolitinib
9.3. Amlexanox
9.4. KPL
9.5. Apremilast
9.6. Tacrolimus
9.7. Research programme: lichen planus therapeutics
9.8. Nanosomal tacrolimus

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. LICHEN PLANUS - UNMET NEEDS

12. LICHEN PLANUS - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Lichen Planus Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Lichen Planus companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Lichen Planus Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

AFYX Therapeutics
Genentech
Incyte Corporation
Takeda
Biogen
Intas Pharmaceuticals
Helsinn
Celgene
Kaken Pharmaceutical
Onxeo
Intas Pharmaceuticals


More Publications